rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
1
|
pubmed:dateCreated |
1996-10-29
|
pubmed:abstractText |
In the present report, we investigated the potential involvement of imidazoline I1 and I2 binding sites in the inhibition of the Ca(2+)-activated K+ channel (Gardos channel) by clotrimazole in human red cells. Ca(2+)-activated 86Rb influx was inhibited by clotrimazole and efaroxan but not by the imidazoline binding site ligands clonidine, moxonidine, cirazoline and idazoxan (100 microM). Binding studies with [3H]idazoxan and [3H]p-aminoclonidine did not reveal the expression of I1 and I2 binding sites in erythrocytes. These data indicate that the effects of clotrimazole and efaroxan on the erythrocyte Ca(2+)-activated K+ channel may be mediated by a 'non-I1/non-I2' binding site.
|
pubmed:grant |
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
0014-2999
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:day |
4
|
pubmed:volume |
295
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
109-12
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:8925867-Adrenergic alpha-Antagonists,
pubmed-meshheading:8925867-Benzofurans,
pubmed-meshheading:8925867-Binding Sites,
pubmed-meshheading:8925867-Calcium,
pubmed-meshheading:8925867-Clotrimazole,
pubmed-meshheading:8925867-Dose-Response Relationship, Drug,
pubmed-meshheading:8925867-Erythrocytes,
pubmed-meshheading:8925867-Humans,
pubmed-meshheading:8925867-Imidazoles,
pubmed-meshheading:8925867-Potassium Channels
|
pubmed:year |
1996
|
pubmed:articleTitle |
Clotrimazole and efaroxan inhibit red cell Gardos channel independently of imidazoline I1 and I2 binding sites.
|
pubmed:affiliation |
INSERM U388, Institut Louis Bugnard, CHU Rangueil, Toulouse, France.
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|